On Mar. 26, 2020, Dynavax and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a collaboration supporting the global effort to develop a vaccine to prevent the coronavirus (COVID-19). Dynavax will make the Companyﾒs proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018TM, available for the development of effective vaccines against COVID-19.